The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma
Official Title: A Phase I Study of Immunotherapy With hA20 Administered Once Weekly for 4 Consecutive Weeks in Patients With CD20+ Non- Hodgkin's Lymphoma
Study ID: NCT00596804
Brief Summary: This study is being done to assess the safety and tolerance of different doses of humanized hA20 in patients with NHL.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Service Des Maladies Du Sang, Lille, Cedex, France
Centre hospitalier Lyon, Lyon, Pierre Benite Cedex, France
University of Leicester, Leicester, , United Kingdom
Name: William Wegener, MD, PhD
Affiliation: Gilead Sciences
Role: STUDY_CHAIR